Announcement • Jun 17
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders StemRIM Inc. announced that a patent will soon be registered in Australia for the application related to the novel treatment of cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) utilizing the peptide drug developed from the "Regeneration-Inducing MedicineTM" development candidate Redasemtide (HMGB1 fragment peptide). Title of Invention Therapeutic agent for cartilage disorder. Region Australia. Application No. 2019367943. Registration No. To be determined . Applicant StemRIM, Osaka University This patent is intended to expand the indications for Redasemtide, which is currently under development, and believe that the granting of this patent will ensure the possibility of developing a drug for cartilage disorders (namely traumatic cartilage defect of joint, osteoarthritis, and osteochondritis dissecans) in Australia. Cartilage disorders cause pain and functional impairment of the joint due to damage or degeneration of cartilage. Because cartilage has limited selfrepair capacity, such disorders tend to become chronic and progressive. It has been confirmed that intravenous administration of Redasemtide mobilizes bone marrow-derived mesenchymal stem cells (MSCs) into the bloodstream and promotes their accumulation at sites of tissue injury. Through this mechanism, Redasemtide is considered to facilitate tissue repair and regeneration in areas of cartilage damage within the knee joint. With its intravenous route of administration, which imposes a relatively low burden on patients, Redasemtide is anticipated to serve as a highly useful therapeutic option in clinical practice. Announcement • Jun 16
StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis StemRIM Inc. announced that a medical use patent for the Regeneration-Inducing MedicineTM development candidate, Redasemtide, indicated for fatty liver and non-alcoholic steatohepatitis, will soon be registered in Russia. Title of Invention: Therapeutic drug for fatty liver and non-alcoholic steatohepatitis. Region: Russia. Application No.: 2024111536. Registration No.: To be determined. Applicant: StemRIM Inc., Osaka University, Niigata University. This patent is intended to expand the indications for Redasemtide, which is currently under development. Fatty liver is a condition in which excess fat accumulates in the liver. Non-alcoholic steatohepatitis (NASH) is a progressive fatty liver disease caused by factors other than alcohol consumption characterized by inflammation and fibrosis of the liver, which, if left untreated, can lead to cirrhosis or liver cancer. Both fatty liver and NASH are expected to see an increase in patient numbers due to the rising prevalence of obesity and diabetes. However, there are currently no effective drug treatments available, and dietary and exercise therapy remain the main approaches. The development of new therapeutic drugs and regenerative medicine is urgently needed. The impact on the financial performance for the fiscal year ending July 31, 2026, is insignificant. The terms "fatty liver" and "non-alcoholic steatohepatitis (NASH)" have been renamed to "steatotic liver disease (SLD)" and "metabolic dysfunction associated steatohepatitis (MASH)," respectively. 
